Loading...

Savara ($SVRA)

Stock Image

SVRA Overview

Savara operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis.The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.Savara Inc. is headquartered in Austin, Texas. (From: StockAnalysis.com)

MORE ABOUT Savara

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.